Ribo Biopharma and PHEIRON Enter Strategic Collaboration to Accelerate AI-Driven RNA Drug Discovery

Recently, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure) announced a strategic partnership with PHEIRON. The collaboration will leverage PHEIRON's advanced AI platform, PheironGPS, to accelerate the development of RNA drugs by Ribo Life Science. This partnership aims to enhance Ribo Life Science’s capabilities in the cardiovascular metabolic disease field by integrating large-scale human multi-omics genetic data generated through PHEIRON’s cutting-edge artificial intelligence technology.

PheironGPS systematically integrates large-scale human multi-omics genetic data to precisely determine its biological mechanisms and provide clear insights into the relationship between drug targets and patient populations. This collaboration will establish a strong scientific link between drug targets and disease causality, offering unprecedented guidance for Ribo Life Science's RNA drug development.

     Dr. Gan Liming, Co-CEO of Ribo Life Science and President of Global Drug Research and Development, stated:"We are delighted to collaborate with PHEIRON's professional AI scientists. Their proprietary AI algorithms, combined with multi-omics genetic information from the general population and highly enriched patient groups, along with our experienced scientists and drug developers, will help uncover complex pathophysiological relationships. This collaboration will significantly enhance the success rate of our innovative drug development in the cardiometabolic field."

    Thore Buergel, CEO of PHEIRON, stated:"Large-scale human datasets are transforming the way we understand and treat diseases. PheironGPS places multi-omics data derived from humans at the forefront of decision-making, providing clear insights into disease mechanisms and patient populations, significantly increasing the likelihood of successful drug development. We are excited to collaborate with Ribo Life Science and Ribocure, leveraging data from large human populations to jointly shape the next generation of RNA therapeutics."